Investigation of NTRK family expression and the durg sensitvie in lung cancer
| Project/Area Number |
26861125
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
Tatematsu Tsutomu 名古屋市立大学, 医学(系)研究科(研究院), 研究員 (40721874)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SASAKI Hidefumi 名古屋市立大学, 大学院医学部医学研究科, 研究員 (00336695)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | NTRK / AZD7451 / fusion / KM12 / LCNEC / 転座 |
|---|
| Outline of Final Research Achievements |
We investigated NTRK1 fusion about 268 Japanese lung cancer patients. However, we were unable to confirm the presence of NTRK fusions in this cohort.
We also investigated the drug sensitive of NTRK inhibitor AZD7451 to cell lines with NTRK1 fusion or NTRK2 expression. As a result,The cell proliferation of the cell lines with NTRK1 fussion or NTRK2 expression was inhibited. Furthermore, we confirmed that the signals concerned in cell proliferation were inhibited , when these cell lines were treated by AZD7451. Therefore, targeted therapy with NTRK inhibitor AZD7451 may be of value in the treatment of lung cancer.
|
Report
(3 results)
Research Products
(3 results)
